Literature DB >> 17210799

Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation.

Austin M Guo1, Ali S Arbab, John R Falck, Ping Chen, Paul A Edwards, Richard J Roman, A Guillermo Scicli.   

Abstract

20-Hydroxyeicosatetraenoic acid (20-HETE) is formed by the omega-hydroxylation of arachidonic acid by cytochrome P450 4A and 4F enzymes, and it induces angiogenic responses in vivo. To test the hypothesis that 20-HETE increases endothelial cell (EC) proliferation via vascular endothelial growth factor (VEGF), we studied the effects of WIT003 [20-hydroxyeicosa-5(Z),14(Z)-dienoic acid], a 20-HETE analog on human macrovascular or microvascular EC. WIT003, as well as pure 20-HETE, stimulated EC proliferation by approximately 40%. These proliferative effects were accompanied by increased VEGF expression and release that were observed as early as 4 h after 20-HETE agonist addition. This was accompanied by increased phosphorylation of the VEGF receptor 2. The proliferative effects of 20-HETE were markedly inhibited by a VEGF-neutralizing antibody. Polyethylene glycol-superoxide dismutase (PEG-SOD) markedly inhibited both the increases in VEGF expression and the proliferative effects of 20-HETE. In contrast, administration of the NAD(P)H oxidase inhibitor apocynin had no effect to the proliferative response to 20-HETE. The 20-HETE agonist markedly increased superoxide formation as reflected by an increase in dihydroethidium staining of EC, and this increase was inhibited by PEG-SOD but not by apocynin. 20-HETE also increased the phosphorylation of p42/p44 mitogen-activated protein kinase (MAPK) in EC, whereas an inhibitor of MAPK [U0126, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] suppressed the proliferative and the VEGF changes but not the pro-oxidant effects of 20-HETE. These data suggest that 20-HETE stimulates superoxide formation by pathways other than apocynin-sensitive NAD(P)H oxidase, thereby activating MAPK and then enhancing VEGF synthesis that drives EC proliferation. Thus, 20-HETE may be involved in the regulation of EC functions, such as angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210799     DOI: 10.1124/jpet.106.115360

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  64 in total

1.  Induction of angiotensin-converting enzyme and activation of the renin-angiotensin system contribute to 20-hydroxyeicosatetraenoic acid-mediated endothelial dysfunction.

Authors:  Jennifer Cheng; Victor Garcia; Yan Ding; Cheng-Chia Wu; Krutanjali Thakar; John R Falck; Errabelli Ramu; Michal Laniado Schwartzman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-06-21       Impact factor: 8.311

Review 2.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 3.  Conflicting roles of 20-HETE in hypertension and renal end organ damage.

Authors:  Chao Zhang; George W Booz; Qing Yu; Xiaochen He; Shaoxun Wang; Fan Fan
Journal:  Eur J Pharmacol       Date:  2018-06-07       Impact factor: 4.432

4.  20-HETE regulates the angiogenic functions of human endothelial progenitor cells and contributes to angiogenesis in vivo.

Authors:  Li Chen; Rachel Ackerman; Mohamed Saleh; Katherine H Gotlinger; Michael Kessler; Lawrence G Mendelowitz; John R Falck; Ali S Arbab; A Guillermo Scicli; Michal L Schwartzman; Jing Yang; Austin M Guo
Journal:  J Pharmacol Exp Ther       Date:  2014-01-08       Impact factor: 4.030

Review 5.  Cytochrome P450 eicosanoids and cerebral vascular function.

Authors:  John D Imig; Alexis N Simpkins; Marija Renic; David R Harder
Journal:  Expert Rev Mol Med       Date:  2011-03-01       Impact factor: 5.600

6.  Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats.

Authors:  Kathryn M Dunn; Marija Renic; Averia K Flasch; David R Harder; John Falck; Richard J Roman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-24       Impact factor: 4.733

7.  A synthetic analogue of 20-HETE, 5,14-HEDGE, reverses endotoxin-induced hypotension via increased 20-HETE levels associated with decreased iNOS protein expression and vasodilator prostanoid production in rats.

Authors:  Tuba Cuez; Belma Korkmaz; C Kemal Buharalioglu; Seyhan Sahan-Firat; John Falck; Kafait U Malik; Bahar Tunctan
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-12-07       Impact factor: 4.080

Review 8.  20-HETE and blood pressure regulation: clinical implications.

Authors:  Cheng-Chia Wu; Tanush Gupta; Victor Garcia; Yan Ding; Michal L Schwartzman
Journal:  Cardiol Rev       Date:  2014 Jan-Feb       Impact factor: 2.644

9.  Interaction Between CYP4F2 rs2108622 and CPY4A11 rs9333025 Variants Is Significantly Correlated with Susceptibility to Ischemic Stroke and 20-Hydroxyeicosatetraenoic Acid Level.

Authors:  Duanxiu Liao; Xingyang Yi; Biao Zhang; Qiang Zhou; Jing Lin
Journal:  Genet Test Mol Biomarkers       Date:  2016-03-09

10.  Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer.

Authors:  Wei Yu; Hongyan Chai; Ying Li; Haixia Zhao; Xianfei Xie; Hao Zheng; Chenlong Wang; Xue Wang; Guifang Yang; Xiaojun Cai; John R Falck; Jing Yang
Journal:  Toxicol Appl Pharmacol       Date:  2012-07-25       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.